Literature DB >> 9829744

High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy.

R A Cooper1, D P Wilks, J P Logue, S E Davidson, R D Hunter, S A Roberts, C M West.   

Abstract

The purpose of this study was to examine the relationship between tumor angiogenesis and prognosis in carcinoma of the cervix treated with radiotherapy with a median follow-up time of 55 months. A retrospective study was carried out on 111 patients. Formalin-fixed, paraffin-embedded tumor biopsies were stained with anti-factor VIII using immunohistochemistry. Tumor angiogenesis was assessed by scoring the distance to the closest microvessel from random points within the tumor and the intratumor microvessel density (IMD) in the areas of highest neovascularization. High vascularity, as measured by both methods, was associated with a poor prognosis but was only significant for IMD. The 5-year survival rates for tumors with high versus low values were 50 and 65%, respectively. IMD was a significant prognostic factor within a Cox multivariate analysis. Higher tumor vascularity was associated with lower overall survival and locoregional control, but this association was not significant in the case of metastasis-free survival. The method used to assess tumor vascularity is important. The level of angiogenesis in carcinoma of the cervix is an independent prognostic parameter.

Entities:  

Mesh:

Year:  1998        PMID: 9829744

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

3.  Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.

Authors:  Cong Zhou; Sarah Taylor; Jonathan Tugwood; Kathryn Simpson; Gordon C Jayson; Paul Symonds; James Paul; Susan Davidson; Karen Carty; Elaine McCartney; Debbie Rai; Caroline Dive; Catharine West
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

Review 4.  Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.

Authors:  Lauren S Krill; Krishnansu S Tewari
Journal:  Clin Ther       Date:  2015-01-01       Impact factor: 3.393

Review 5.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.

Authors:  Vassiliki Kostourou; Helen Troy; Joanne F Murray; Elizabeth R Cullis; Guy St J Whitley; John R Griffiths; Simon P Robinson
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

7.  Contrast-enhanced ultrasonography of cervical carcinoma: perfusion pattern and relationship with tumour angiogenesis.

Authors:  Wei Zheng; Yong-Hong Xiong; Jing Han; Zhi-Xing Guo; Yu-Hong Li; An-Hua Li; Xiao-Qing Pei
Journal:  Br J Radiol       Date:  2016-06-24       Impact factor: 3.039

Review 8.  Importance of adrenergic pathways in women's cancers.

Authors:  Premal H Thaker; Anil K Sood; Lois M Ramondetta
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

Review 9.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

Review 10.  Intra-tumoural microvessel density in human solid tumours.

Authors:  J Hasan; R Byers; G C Jayson
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.